HomeCompareSRCL vs MRK

SRCL vs MRK: Dividend Comparison 2026

SRCL yields 3.23% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $37.5K in total portfolio value
10 years
SRCL
SRCL
● Live price
3.23%
Share price
$61.98
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.2K
Annual income
$0.32
Full SRCL calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — SRCL vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSRCLMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SRCL + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SRCL pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SRCL
Annual income on $10K today (after 15% tax)
$274.28/yr
After 10yr DRIP, annual income (after tax)
$0.27/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MRK beats the other by $8,596.44/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SRCL + MRK for your $10,000?

SRCL: 50%MRK: 50%
100% MRK50/50100% SRCL
Portfolio after 10yr
$39.0K
Annual income
$5,057.05/yr
Blended yield
12.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SRCL
Analyst Ratings
10
Buy
9
Hold
4
Sell
Consensus: Buy
Price Target
$56.33
-9.1% upside vs current
Range: $45.00 — $62.00
Altman Z
2.1
Piotroski
6/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SRCL buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSRCLMRK
Forward yield3.23%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%32.7%
Portfolio after 10y$20.2K$57.7K
Annual income after 10y$0.32$10,113.78
Total dividends collected$326.00$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$56.33$128.54

Year-by-year: SRCL vs MRK ($10,000, DRIP)

YearSRCL PortfolioSRCL Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,861$161.34$11,213$373.04$352.00MRK
2$11,704$81.89$12,667$512.06$963.00MRK
3$12,564$41.23$14,439$708.14$1.9KMRK
4$13,464$20.68$16,640$988.16$3.2KMRK
5$14,417$10.36$19,432$1,394.07$5.0KMRK
6$15,431$5.18$23,057$1,992.90$7.6KMRK
7$16,514$2.59$27,889$2,894.79$11.4KMRK
8$17,671$1.30$34,518$4,286.29$16.8KMRK
9$18,909$0.65$43,912$6,494.35$25.0KMRK
10$20,233$0.32$57,714$10,113.78$37.5KMRK

SRCL vs MRK: Complete Analysis 2026

SRCLStock

Stericycle, Inc., together with its subsidiaries, provides regulated and compliance solutions in the United States, Europe, and internationally. The company offers regulated waste and compliance services, including sharps disposable and management solutions; pharmaceutical waste services; hazardous waste disposal; maritime waste services, such as seaport and airport waste; and compliance programs under the Steri-Safe, Clinical Services, First Practice Management, SeguriMed, and EnviroAssure brand names. It also provides secure information destruction services, including document and hard drive destruction services under the Shred-it brand; and communication solutions, such as appointment reminders, secure messaging, event registration, and other communications specifically for hospitals and integrated delivery networks. The company serves healthcare businesses, including hospitals, physician and dental practices, outpatient clinics, long-term care facilities, etc.; retailers and manufacturers; financial and professional service providers; governmental entities; and other businesses. Stericycle, Inc. was incorporated in 1989 and is headquartered in Bannockburn, Illinois.

Full SRCL Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this SRCL vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SRCL vs SCHDSRCL vs JEPISRCL vs OSRCL vs KOSRCL vs MAINSRCL vs JNJSRCL vs ABBVSRCL vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.